Test Price
2,800 AED✅ Home Collection Available
DYM Gene Next-Generation Sequencing (NGS) Test for Dyggve-Melchior-Clausen Syndrome in Dubai, UAE
Executive Summary & Core Metrics
- Diagnostic Accuracy: 99.9% sensitivity and specificity via ISO 9001:2015 accredited NGS platform for full DYM gene coding region analysis.
- Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection available daily from 8 AM to 11 PM across all Emirates.
- Clinical Guidance: Post-test telephonic result interpretation and genetic counselling by a DHA-licensed Consultant Medical Geneticist.
- Insurance Verification: Direct billing support and coverage confirmation via WhatsApp +971 54 548 8731.
Test Overview & Methodology
This genetic test employs advanced Next-Generation Sequencing (NGS) to comprehensively analyze the DYM gene, which is responsible for Dyggve-Melchior-Clausen (DMC) syndrome. DMC syndrome is a rare autosomal recessive disorder characterized by skeletal dysplasia, intellectual disability, and distinctive radiographic findings. Our targeted NGS assay provides complete coverage of the DYM gene coding exons and flanking intronic regions, enabling high-confidence detection of point mutations, small insertions, deletions, and splice-site variants. This test is essential for establishing a definitive diagnosis in symptomatic children, guiding family planning through carrier screening, and enabling early therapeutic interventions.
Comparative Analysis: NGS vs. Alternative Sequencing Methods
| Feature | DYM NGS Full Gene Test | Traditional Sanger Sequencing | Whole Exome Sequencing |
|---|---|---|---|
| Target Precision | 100% coding region coverage with deep sequencing depth (≥100x) | Limited to known familial mutations; low throughput | Genome-wide but lower depth for the DYM locus (~30–50x) |
| Turnaround Time | 3–4 Weeks | 4–6 Weeks | 6–8 Weeks |
| Clinical Utility | Optimal for diagnostic confirmation and carrier screening | Low diagnostic yield for novel variants | Risk of incidental findings; higher cost per test |
Physician Insight & Safety Protocols
"A confirmed diagnosis of Dyggve-Melchior-Clausen syndrome through targeted DYM gene sequencing fundamentally changes the management pathway for the patient and their family. The test result must always be interpreted alongside detailed clinical phenotyping, including growth charts, skeletal surveys, and neurodevelopmental assessments. A negative NGS result does not fully exclude the syndrome, as non-coding or structural variants may elude current capture methods. Conversely, a clearly pathogenic finding enables proactive, multidisciplinary care involving orthopedics, neurology, and genetic counselling. I always advise patients that this test is a starting point, not an endpoint, for comprehensive clinical decision-making."
— Mrs. Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Patient Safety Exclusion Criteria & Emergency Red Flags
- Exclusion Criteria: This test is not recommended for asymptomatic minors without prior genetic counselling and signed informed parental consent. Patients with known bleeding disorders or those taking anticoagulant therapy must inform the phlebotomist before venipuncture to mitigate hematoma risk.
- Emergency Red Flags: Seek immediate medical attention at the nearest emergency department if you experience uncontrolled bleeding from the collection site, localized erythema with pus or systemic fever indicating infection, or signs of a severe allergic reaction including difficulty breathing, facial swelling, or widespread urticaria.
Patient FAQ & Clinical Guidance
1. What is the DYM Gene NGS Test for Dyggve-Melchior-Clausen disease?
This test uses Next-Generation Sequencing to analyze the entire coding region of the DYM gene. It detects point mutations, small insertions, deletions, and splice-site variants to diagnose or rule out Dyggve-Melchior-Clausen syndrome, a rare autosomal recessive condition involving skeletal abnormalities and intellectual disability. Analysis is performed on genomic DNA extracted from a standard peripheral blood sample.
2. How long does it take to receive the results in the UAE?
The total turnaround time for the DYM gene NGS test is typically 3 to 4 weeks from the date of sample receipt at our Dubai Healthcare City laboratory. This includes DNA extraction, library preparation, high-throughput sequencing, bioinformatics alignment and variant calling, and a final clinical interpretation report authored by a DHA-licensed Consultant Medical Geneticist. Urgent requests may be expedited on a case-by-case basis upon consultation.
3. Is home sample collection available across all Emirates?
Yes, we provide VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection services to patients in Dubai, Abu Dhabi, Sharjah, Ajman, Ras Al Khaimah, Fujairah, and Umm Al Quwain. Our trained nursing professionals visit your residence or office daily between 8 AM and 11 PM, using sterile equipment and cold-chain packaging to maintain specimen integrity from collection through transport to our ISO-accredited laboratory.
4. What information will the clinical report include?
Your final report will include: (i) a summary of all detected DYM gene variants with their genomic coordinates and predicted protein impact, (ii) pathogenicity classifications based on ACMG/AMP guidelines, (iii) clinical correlation with typical DMC syndrome findings, (iv) recommendations for confirmatory testing or family cascade screening, and (v) contact information for post-test telephonic counselling by our consultant geneticist.
5. Can this test be used for prenatal diagnosis?
Yes, the DYM gene NGS test can be performed on chorionic villus samples (CVS) or amniotic fluid specimens when there is a known familial DYM mutation or ultrasound findings suggestive of DMC syndrome. However, prenatal testing requires mandatory pre-test genetic counselling, written informed consent from both parents, and coordination with a maternal-fetal medicine specialist. Please contact our laboratory to initiate the prenatal testing workflow.
UAE Regulatory & Data Privacy Adherence
DNA Labs UAE operates under the strict governance of Dubai Healthcare City (DHCC) and complies with all applicable UAE federal laws concerning medical data and patient privacy. Our clinical and bioinformatics workflows adhere to Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL), ensuring that your genetic information is encrypted, access-controlled, and never shared without explicit consent. We also observe Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields, which governs the secure transmission and storage of electronic health records. All clinical testing services are conducted in alignment with Federal Decree-Law No. 4 of 2016 on Medical Liability, guaranteeing patient safety and professional accountability throughout the diagnostic journey.
Clinical & Logistical Metadata
| Test Name | DYM Gene Full Gene NGS Sequencing |
| Price (AED) | 2800 |
| Turnaround Time | 3–4 Weeks |
| Sample Type / Matrix | Peripheral Whole Blood (Standard Venipuncture) |
| Methodology Used | Next-Generation Sequencing (NGS) |
| ICD-10-CM Code | Q87.1 |
| LOINC Code | 16994-7 |
| DHA Facility License & Laboratory Address | License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians